Drug Development

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

A Swiss-Indian partnership aims to halt diseases like Alzheimer's and ALS by repairing damaged cell membranes, a groundbreaking approach to a global crisis.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

A new partnership combines local infrastructure with global expertise, aiming to streamline development for startups and solidify Singapore's biotech leadership.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.